Welcome to the Cancer Genomics and Translational Research Laboratory.
Our laboratory bridges basic and clinical research to study drug resistance in breast cancer patients. Our research focuses mainly on triple-negative and Her2+ breast cancers, the most aggressive breast cancer subtypes. Through collaborative projects, we also study drug resistance in colon and gastric cancers. Most cancer patients inevitably develop drug resistance at some point during their treatment. Our team makes use of cutting-edge technologies and patient specimens to further understand the mechanisms behind the emergence of resistance; identify novel therapeutic targets as well as biomarkers to monitor recurrence. The ultimate objective of our work is to circumvent resistance and improve cancer therapy to benefit cancer patients.
Our laboratory is part of the Segal Cancer Centre and the Lady Davis
Institute for Medical Research, both affiliated to McGill University in Montreal.